Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Healthtrust
Mallinckrodt
US Army
UBS
Boehringer Ingelheim
Citi
Fish and Richardson
Cipla
Cerilliant
Express Scripts

Generated: February 25, 2018

DrugPatentWatch Database Preview

Shionogi Company Profile

« Back to Dashboard

What is the competitive landscape for SHIONOGI, and when can generic versions of SHIONOGI drugs launch?

SHIONOGI has nine approved drugs.

There are six US patents protecting SHIONOGI drugs on SHIONOGI drugs in the past three years.

There are sixty patent family members on SHIONOGI drugs in twenty countries and fourteen supplementary protection certificates in seven countries.

Summary for Shionogi
International Patents:60
US Patents:6
Tradenames:9
Ingredients:8
NDAs:9

Drugs and US Patents for Shionogi

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Shionogi Inc ULESFIA benzyl alcohol LOTION;TOPICAL 022129-001 Apr 9, 2009 RX Yes Yes 6,793,931 ➤ Sign Up Y ➤ Sign Up
Shionogi Inc PONSTEL mefenamic acid CAPSULE;ORAL 015034-003 Approved Prior to Jan 1, 1982 AB RX Yes Yes ➤ Sign Up ➤ Sign Up
Shionogi Inc SYMPROIC naldemedine tosylate TABLET;ORAL 208854-001 Mar 23, 2017 RX Yes Yes 9,108,975 ➤ Sign Up Y Y ➤ Sign Up
Shionogi Inc ULESFIA benzyl alcohol LOTION;TOPICAL 022129-001 Apr 9, 2009 RX Yes Yes 7,294,342 ➤ Sign Up ➤ Sign Up
Shionogi Inc RYBIX ODT tramadol hydrochloride TABLET, ORALLY DISINTEGRATING;ORAL 021693-001 May 5, 2005 DISCN No No ➤ Sign Up ➤ Sign Up
Shionogi Inc COGNEX tacrine hydrochloride CAPSULE;ORAL 020070-003 Sep 9, 1993 DISCN No No ➤ Sign Up ➤ Sign Up
Shionogi UROPLUS SS sulfamethoxazole; trimethoprim TABLET;ORAL 071815-001 Sep 28, 1987 DISCN No No ➤ Sign Up ➤ Sign Up
Shionogi Inc COGNEX tacrine hydrochloride CAPSULE;ORAL 020070-001 Sep 9, 1993 DISCN No No ➤ Sign Up ➤ Sign Up
Shionogi Inc DORIBAX doripenem INJECTABLE;IV (INFUSION) 022106-002 Oct 5, 2010 DISCN Yes No 8,247,402 ➤ Sign Up Y Y ➤ Sign Up
Shionogi UROPLUS DS sulfamethoxazole; trimethoprim TABLET;ORAL 071816-001 Sep 28, 1987 DISCN No No ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for Shionogi

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Shionogi Inc COGNEX tacrine hydrochloride CAPSULE;ORAL 020070-001 Sep 9, 1993 4,631,286 ➤ Sign Up
Shionogi Inc COGNEX tacrine hydrochloride CAPSULE;ORAL 020070-002 Sep 9, 1993 4,816,456 ➤ Sign Up
Shionogi Inc DORIBAX doripenem INJECTABLE;IV (INFUSION) 022106-002 Oct 5, 2010 5,317,016 ➤ Sign Up
Shionogi Inc COGNEX tacrine hydrochloride CAPSULE;ORAL 020070-003 Sep 9, 1993 4,631,286 ➤ Sign Up
Shionogi Inc COGNEX tacrine hydrochloride CAPSULE;ORAL 020070-004 Sep 9, 1993 4,631,286 ➤ Sign Up
Shionogi Inc DORIBAX doripenem INJECTABLE;IV (INFUSION) 022106-001 Oct 12, 2007 5,317,016 ➤ Sign Up
Shionogi Inc COGNEX tacrine hydrochloride CAPSULE;ORAL 020070-004 Sep 9, 1993 4,816,456 ➤ Sign Up
Shionogi Inc COGNEX tacrine hydrochloride CAPSULE;ORAL 020070-003 Sep 9, 1993 4,816,456 ➤ Sign Up
Shionogi Inc RYBIX ODT tramadol hydrochloride TABLET, ORALLY DISINTEGRATING;ORAL 021693-001 May 5, 2005 6,106,861 ➤ Sign Up
Shionogi Inc COGNEX tacrine hydrochloride CAPSULE;ORAL 020070-001 Sep 9, 1993 4,816,456 ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for SHIONOGI drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Lotion 5% ➤ Subscribe 4/11/2016
➤ Subscribe Injection 250 mg/vial and 500 mg/vial ➤ Subscribe 10/11/2011

Non-Orange Book US Patents for Shionogi

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,221,823 Crystal form of pyrrolidylthiocarbapenem derivative ➤ Sign Up
9,464,094 Crystal of 6,7-unsaturated-7-carbamoyl morphinan derivative and method for producing the same ➤ Sign Up
8,084,460 6,7-unsaturated-7-carbamoyl substituted morphinan derivative ➤ Sign Up
8,536,192 6,7-unsaturated-7-carbamoyl substituted morphinan derivative ➤ Sign Up
9,296,756 Crystal of 6,7-unsaturated-7-carbamoyl morphinan derivative and method for producing the same ➤ Sign Up
9,315,512 Crystal of 6,7-unsaturated-7-carbamoyl morphinan derivative and method for producing the same ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Supplementary Protection Certificates for Shionogi Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB01/002 United Kingdom ➤ Sign Up PRODUCT NAME: 5-(4-(2-(N-METHYL-N-(2-PYRIDYL)AMINO)ETHOXY) BENZYL)-2,4-THIAZOLIDINEDIONE, "ROSIGLITAZONE" ITS TAUTOMERS, PHARMACEUTICALLY ACCEPTABLE SALTS, SUCH AS THE MALEATE, AND PHARMACEUTICALLY ACCEPTABLE SOLVATES.; REGISTERED: CH 55176 02 19990929; CH 55176 03 19990929; CH 55176 04 19990929; UK EU/1/00/137/001 20000711; UK EU/1/00/137/002 20000711; UK EU/1/00/137/003 20000711; UK EU/1/00/137/004 20000711; UK EU/1/00/137/005 20000711; UK EU/1/00/137/006 20000711; UK EU/1/00/137/007 20000711; UK EU/1/00/137/008 20000711; UK EU/1/00/137/009 20000711; UK EU/1/00/137/010 20000711; UK EU/1/00/137/011 20000711; UK EU/1/00/137/012 20000711
2009 00003 Denmark ➤ Sign Up PRODUCT NAME: DORIPENEM, HERUNDER DORIPENEMMONOHYDRAT; REG. NO/DATE: EU/1/08/467/001 20080725
C0041 France ➤ Sign Up PRODUCT NAME: CYCLO((4R)-4(2-AMINOETHYLCARBAMOYLOXY)-L-PROLYL-L-PHENYLGLYCYL-D-TRYPTOPHYL-L-LYSYL-4-O-BENZYL-L-TYROSYL-L-PHENYLALANYL-) : PASIREOTIDE, OU SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; REGISTRATION NO/DATE: EU/1/12/753/001 20120424
3 Finland ➤ Sign Up
00374 Netherlands ➤ Sign Up PRODUCT NAME: DORIPENEM; REGISTRATION NO/DATE: EU/1/08/467/001 20080725
C0005 France ➤ Sign Up PRODUCT NAME: DORIPENEME; REGISTRATION NO/DATE IN FRANCE: EU/1/07/467/001 DU 20080725; REGISTRATION NO/DATE AT EEC: EU/1/08/467/001 DU 20080725
C/GB09/006 United Kingdom ➤ Sign Up PRODUCT NAME: DORIPENEM; REGISTERED: UK EU/1/08/467/001 20080725
C/GB04/012 United Kingdom ➤ Sign Up PRODUCT NAME: TRAMADOL HYDROCHLORIDE, PARACETAMOL; REGISTERED: FR NL 25970 20020405; UK PL 00242/0384 20030925
C/GB01/003 United Kingdom ➤ Sign Up PRODUCT NAME: N-(4-(2(N-METHYL-N-(2-PYRIDYL)AMINO)ETHOXY)BENZYL)THIAZOLIDINE-2,4-DIONE MALEIC ACID, "ROSIGLITAZONE MALEATE", ITS TAUTOMERS AND PHARMACEUTICALLY ACCEPTABLE SOLVATES; REGISTERED: CH 55176 02 19990929; CH 55176 03 19990929; CH 55176 04 19990929; UK EU/1/00/137/001 20000711; UK EU/1/00/137/002 20000711; UK EU/1/00/137/003 20000711; UK EU/1/00/137/004 20000711; UK EU/1/00/137/005 20000711; UK EU/1/00/137/006 20000711; UK EU/1/00/137/007 20000711; UK EU/1/00/137/008 20000711; UK EU/1/00/137/009 20000711; UK EU/1/00/137/010 20000711; UK EU/1/00/137/011 20000711; UK EU/1/00/137/012 20000711
09/002 Ireland ➤ Sign Up PRODUCT NAME: DORIPENEM.; REGISTRATION NO/DATE: EU/1/08/467/001 20080725
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Dow
Fuji
UBS
Cerilliant
Cipla
Federal Trade Commission
Johnson and Johnson
McKinsey
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot